



## Announcement Summary

---

**Name of entity**

MAYNE PHARMA GROUP LIMITED

**Announcement type**

Update announcement

**Type of update**

☒ Correction to previous announcement

**Date of this announcement**

3/4/2023

**Reason for update**

Correction to the value of the employee share loans being extinguished in section 3A.9b.

**ASX Security code and description of the class of +securities the subject of the buy-back**

MYX : ORDINARY FULLY PAID

**The type of buy-back is:**

☒ Employee share scheme buy-back

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

MAYNE PHARMA GROUP LIMITED

We (the entity named above) provide the following information about our buy-back.

**1.2 Registration number type**

ACN

**Registration number**

115832963

**1.3 ASX issuer code**

MYX

**1.4 The announcement is**

☒ Update/amendment to previous announcement

**1.4a Type of update**

☒ Correction to previous announcement

**1.4b Reason for update**

Correction to the value of the employee share loans being extinguished in section 3A.9b.

**1.4c Date of initial notification of buy-back**

30/3/2023

**1.4d Date of previous announcement to this update**

30/3/2023

**1.5 Date of this announcement**

3/4/2023

**1.6 ASX Security code and description of the class of +securities the subject of the buy-back**

MYX : ORDINARY FULLY PAID



## Part 2 - Type of buy-back

---

### 2.1 The type of buy-back is:

☒ Employee share scheme buy-back



### Part 3 - Buy-back details

---

#### Part 3A - Details of +securities, price and reason

---

**3A.1 Total number of +securities on issue in the class of +securities to be bought back**

85,776,451

**3A.2 Total number of +securities proposed to be bought back**

702,163

**3A.9 Are the +securities being bought back for a cash consideration?**

☒ No

**3A.9b Please describe the consideration being provided to buy back the +securities**

Extinguishment of employee share loans totalling \$10,700,964 originally advanced by the Company to the employees concerned for the purchase of the loan scheme shares being cancelled. No cash is payable by the Company for the buy back.

#### Part 3B - Buy-back restrictions and conditions

---

**3B.1 Does the buy-back require security holder approval?**

☒ No

**3B.3 Are there any other conditions that need to be satisfied before the buy-back offer becomes unconditional?**

☒ No



## Part 3C - Key dates

---

### Employee Share Scheme, Selective and Other Buy-Backs

#### 3C.1 Anticipated date buy-back will occur

31/3/2023

## Part 3D - Other Information

---

#### 3D.1 Any other information the entity wishes to notify to ASX about the buy-back

In accordance with the terms of the Mayne Pharma Group Employee Loan plan, the Company is buying back and cancelling employee loan shares that have reached the grant expiry date and become forfeited shares as the performance conditions were not met or the share price was lower than the issue price of the shares. These shares were issued to employees in 2018.